Examining downstream effects of concizumab in hemophilia A with a mathematical modeling approach
The effectiveness of concizumab is mediated through the blockade of TFPI anticoagulant activities in plasma and on multiple physiological surfaces. An important and previously unrecognized function of concizumab was the sequestration of plasma TFPIα to the endothelium.
Authors
- Alan E. Mast (ORCID: https://orcid.org/0000-0003-3740-0318)
- Karin Leiderman (ORCID: https://orcid.org/0000-0002-4188-1305)
- Michael Dockal
- Marianne Kjalke
- Adam R. Wufsus
- Kenji Miyazawa (ORCID: https://orcid.org/0000-0002-4091-3184)
Institutions
- University of North Carolina at Chapel Hill (US)
- Colorado School of Mines (US)
- Novo Nordisk (Denmark) (DK)
- Quantitative BioSciences (US)
- Novo Nordisk (United States) (US)
- Versiti Blood Center of Wisconsin (US)
- Novo Nordisk (Italy) (IT)
Publication Details
- Journal
- Journal of Thrombosis and Haemostasis
- Published
- 2024-11-12
- DOI
- https://doi.org/10.1016/j.jtha.2024.10.028
- Citations
- 1
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- National Science Foundation
- Foundation for the National Institutes of Health
- Novo Nordisk
- National Institutes of Health
- Division of Mathematical Sciences